This article is more than 5 years old. Information may no longer be current.
Top stories in cardiology: FDA approves cardiomyopathy treatments, vagus nerve stimulation reduces atrial fibrillation burden
The top story in cardiology last week was the FDA approving two treatments for patients with cardiomyopathy from transthyretin-mediated amyloidosis.
Other highlights were reports from the Heart Rhythm Society Annual Scientific Sessions which included research that determined transcutaneous electrical stimulation of the vagus nerve reduced atrial fibrillation burden, a study that found his bundle pacing was not superior to biventricular pacing in cardiac resynchronization therapy, trial results that indicated prophylactic implantation of an implantable cardioverter defibrillator within 90 days of undergoing percutaneous coronary intervention for ST-elevation myocardial infarction reduced risk for death in certain high-risk patients and a study that found left atrial appendage ablation may raise risk for stroke and transient ischemic attack.
Treatments for cardiomyopathy from transthyretin-mediated amyloidosis approved by FDA
The FDA approved two treatments for patients with cardiomyopathy associated with transthyretin-mediated amyloidosis. Read more.
TREAT-AF: Vagus nerve stimulation reduces atrial fibrillation burden
SAN FRANCISCO — Transcutaneous electrical stimulation of the vagus nerve reduced atrial fibrillation burden compared with a sham procedure, researchers from the TREAT-AF study reported at the Heart Rhythm Society Annual Scientific Sessions. Read more.
His-SYNC: His bundle pacing not superior to biventricular pacing in cardiac resynchronization therapy
SAN FRANCISCO — His bundle pacing as first-line therapy did not improve ECG or echocardiographic parameters compared with biventricular pacing in patients with HF requiring cardiac resynchronization therapy, a speaker said. Read more.
Implantable defibrillator benefits high-risk patients after p ercutaneous coronary intervention for ST-elevation myocardial infarction
SAN FRANCISCO — Prophylactic implantation of an implantable cardioverter defibrillator within 90 days of undergoing percutaneous coronary intervention for ST-elevation myocardial infarction reduced risk for death in certain high-risk patients, according to the results of the DAPA trial. Read more.
Left atrial appendage ablation may raise risk for stroke, transient ischemic attack
SAN FRANCISCO — Among patients who underwent catheter ablation for atrial fibrillation, those who had left atrial appendage ablation with or without isolation had elevated risk for ischemic stroke or transient ischemic attack, according to a speaker. Read more.